Clinical Trials Logo

Clinical Trial Summary

The objective of the present study is to evaluate both the efficacy and safet of nateglinide in renal transplanta recipients with posttransplant diabetes mellitus or impaired glucose tolerance. Primarily will the change in glucose tolerance and acute insuline responce be addressed.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00319189
Study type Interventional
Source University of Oslo School of Pharmacy
Contact
Status Completed
Phase Phase 4
Start date November 2002
Completion date November 2003

See also
  Status Clinical Trial Phase
Terminated NCT02956005 - Envarsus XR in African American Renal Transplant Recipients N/A
Completed NCT01086904 - Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients Phase 2
Completed NCT01859832 - Validation of a Novel Diagnostic Tool for the Evaluation of Post Renal Transplant Immunosuppression: The ImmuKnow Assay N/A
Recruiting NCT03110406 - Effects of Whole-body Vibration Training on the Heart Rate Variability Cardiac in Kidney Transplantation N/A
Recruiting NCT02973464 - The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population Phase 3
Active, not recruiting NCT03797196 - RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients Phase 4
Terminated NCT01318915 - Research Study of ATG and Rituximab in Renal Transplantation Early Phase 1
Recruiting NCT00327483 - Web Based Renal Transplant Patient Medication Education Phase 4
Terminated NCT00271830 - Sexual Function in Male Renal Transplant Patients N/A
Completed NCT00138970 - Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk Phase 4
Withdrawn NCT04903054 - Selective CD28 Blockade in Renal Transplant Recipients Phase 2
Completed NCT02706678 - Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients Phase 4
Active, not recruiting NCT04218721 - Implementing eHealth Interventions Into Regular Clinical Practice N/A
Recruiting NCT03726307 - Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study Phase 1